Biomatrix Research Inc. (Japan)

Biomatrix Research Inc. (株式会社バイオマトリックス研究所) is a Japanese life-science company headquartered in Nagareyama, Chiba Prefecture, that develops, manufactures and sells monoclonal antibodies. These antibodies serve as the critical raw material for rapid diagnostic test kits, and the company positions itself as a "Japanese-quality antibody supplier" contributing to appropriate medical care worldwide. The company was established on 28 March 2002 in Noda, Chiba Prefecture, initially pursuing transcription-factor antibody development and commissioned genetic analysis services such as microarrays and sequencing. Over the following two decades it relocated several times within Chiba Prefecture, opened a sales office in Osaka, and progressively concentrated its business on antibodies. A pivotal shift came in 2007 when it began developing raw antibodies for influenza rapid diagnostic kits, followed by commercial sales in 2010. In 2012 management was restructured and resources were focused on antibody development, manufacturing and sales. The company later expanded into tropical infectious diseases, starting malaria antibody sales in 2018, and rebuilt its head office building in 2022. Biomatrix Research's product lines cover respiratory infections (Influenza A and B, SARS-CoV-2, adenovirus, RSV, Mycoplasma), tropical infections (malaria HRP-2, malaria pf-LDH, malaria pv-LDH, malaria pk-LDH, malaria pan-LDH, Zika, dengue, chikungunya), transcription factors (TF), and other reagents such as anti-human IgG, anti-human IgM and CPV. The company states that it holds roughly 60% of the global share for influenza diagnostic antibodies (by its own estimate) and supplies diagnostic kit makers and research institutions in Japan and around the world. It also pursues joint research and global development, including products adopted by the World Health Organization (WHO). Biomatrix Research is a private company with stated capital of 95,500 thousand yen (as of 31 December 2025). Its representative director is Osamu Nomura. The business model centers on supplying the antibody "core" that determines diagnostic kit performance, thereby contributing to early detection and containment of infectious diseases.

Biomatrix Research Inc. was established on 28 March 2002 in Noda, Chiba Prefecture, Japan. At its founding the company began two lines of work: the development of transcription-factor antibodies and commissioned genetic information analysis services, including microarray and sequencing. In August 2003 the company moved its head-office functions and sales base to Kashiwa, Chiba Prefecture, and opened a laboratory at the Tokatsu Techno Plaza. In January 2004 it opened a sales office in Nishi-ku, Osaka, and in November 2004 it opened a laboratory at the University of Tokyo Kashiwa Venture Plaza in Kashiwa, Chiba Prefecture. In March 2006 the head office was relocated to Nagareyama, Chiba Prefecture. A decisive strategic turn came in December 2007, when the company began developing raw antibodies for influenza rapid diagnostic kits. Commercial sales of these influenza diagnostic raw antibodies started in August 2010. In March 2012 the company renewed its management structure and concentrated its management resources on the development, manufacturing and sales of antibodies. In April 2015 it consolidated its business sites at the Nagareyama head office. In March 2016 it began developing raw antibodies for tropical infectious diseases, and in March 2018 it started selling antibodies for malaria detection. In October 2022 the company rebuilt its head office building. Today Biomatrix Research develops monoclonal antibodies in-house for infectious disease diagnostics such as influenza, malaria and dengue, manufactures them at its head office and through external contractors, and supplies them to diagnostic kit manufacturers and research institutions in Japan and worldwide. The company states that it has achieved approximately 60% of the global share for influenza diagnostic antibodies (by its own estimate). It also pursues joint research and global expansion, including products adopted by the World Health Organization (WHO), and engages in technical alliances and strategic planning based on direct customer feedback.

• 2022

  Head office building rebuilt.

• 2018

  Started sales of antibodies for malaria detection.

• 2016

  Began development of raw antibodies for tropical infectious diseases.

• 2015

  Business sites consolidated at the Nagareyama head office.

• 2012

  Management structure renewed; resources concentrated on antibody development, manufacturing and sales.

• 2010

  Started sales of raw antibodies for influenza rapid diagnostic kits.

• 2007

  Began development of raw antibodies for influenza rapid diagnostic kits.

• 2006

  Head office relocated to Nagareyama, Chiba Prefecture.

• 2004

  Sales office opened in Nishi-ku, Osaka.

• 2004

  Laboratory opened at University of Tokyo Kashiwa Venture Plaza, Kashiwa, Chiba Prefecture.

• 2003

  Head-office functions and sales base moved to Kashiwa, Chiba Prefecture; laboratory opened at Tokatsu Techno Plaza.

• 2002

  Company established in Noda, Chiba Prefecture; begins transcription-factor antibody development and commissioned genetic analysis (microarray, sequencing).

Japanese-quality monoclonal antibody supplier providing the critical raw material for infectious disease diagnostic kits, contributing to early detection and containment of infections worldwide.

• Influenza A antibody

• Influenza B antibody

• SARS-CoV-2 antibody

• Adenovirus antibody

• RSV antibody

• Mycoplasma antibody

• Malaria HRP-2 antibody

• Malaria pf-LDH antibody

• Malaria pv-LDH antibody

• Malaria pk-LDH antibody

• Malaria pan-LDH antibody

• Zika antibody

• Dengue antibody

• Chikungunya antibody

• Transcription factor (TF) antibody

• anti-human IgG

• anti-human IgM

• CPV antibody

1. 1株式会社バイオマトリックス研究所 コーポレートサイトbiomatrix.co.jp
2. 2会社概要 | 株式会社バイオマトリックス研究所biomatrix.co.jp
3. 3Biomatrix Research Inc. (Japan) - Wikidatawikidata.org